• NYSE | ELN | 7.60 | +0.60  (20 minute delay)
 


HBO Alzheimers Project

Elan_Pharmatrophix

Alzheimer's join the fight

               These are large files please allow sufficient time to download
 

Feature:

  • WEBCAST REPLAY: Elan Discusses Agreement for Alzheimer’s Immunotherapy Program and Equity Investment...more 
  • Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer’s Immunotherapy Program and Equity Investment...more
  • Fampridine-SR Licensed in markets outside the United States...more
  • Elan and PharmatrophiX Announce Collaborative Pact...more
  • Elan Announces Date of 2009 Annual General Meeting and Changes in Board of Directors...more  

Marketed Products
in the U.S.


 

Medical Information Requests

In response to unsolicited requests, Elan provides updated medical information on all of its marketed products, including safety and efficacy information, to U.S. healthcare professionals. For additional information, please go to U.S. Medical Information. All product information provided is intended for U.S. healthcare professionals only. If you are a patient, or are not a healthcare professional, and would like more information about any of these products, their uses and potential side effects, please contact your doctor so that your doctor can access relevant medical information on Elan products. These products may not be available in countries outside the United States or may be available under a different trademark; in different strengths; or for different indications. Countries outside the United States may have different regulatory requirements that would call for different information to be available; product information for countries other than the United States is not available at this time.